Keywords: up, 448m, govt, biothrax, contract, emergent, biosolutions

Up to $448M US govt BioThrax contract

Article | 6 October 2008

• Print This

Emergent BioSolutions that it has signed a new, multi-year, firm fixed price contract with the US Department of Health and Human Services to supply an additional 14.5 million doses of BioThrax (anthrax vaccine adsorbed), its Food and Drug Administration-licensed anthrax vaccine, for inclusion in the Strategic National Stockpile.

The total value of this follow-on contract is between $364.0 million and $404.0 million, with the higher amount tied to the delivery of product having four-year expiry dating. First deliveries of BioThrax under this new contract are scheduled to begin in third-quarter 2009, immediately following the scheduled completion of deliveries under the company's current $448.0 million contract to supply 18.75 million doses of BioThrax to the SNS. Final product deliveries under this new contract are anticipated in third-quarter 2011.

Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.